{
  "name" : "dacemirror.sci-hub.se_journal-article_e8d9aaf75f4d9a2a16d786a5a9f227e7_choi2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Hyaluronic Acid–Based Activatable Nanomaterials for Stimuli- Responsive Imaging and Therapeutics: Beyond CD44-Mediated Drug Delivery",
    "authors" : [ "Ki Young Choi", "Hwa Seung Han", "Eun Sook Lee", "Jung Min Shin", "Benjamin D. Almquist", "Doo Sung Lee", "Jae Hyung Park" ],
    "emails" : [ "jhpark1@skku.edu" ],
    "sections" : [ {
      "heading" : null,
      "text" : "PROGRESS REPORT\n1803549 (1 of 18) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de\nHyaluronic Acid–Based Activatable Nanomaterials for StimuliResponsive Imaging and Therapeutics: Beyond CD44-Mediated Drug Delivery"
    }, {
      "heading" : "Ki Young Choi, Hwa Seung Han, Eun Sook Lee, Jung Min Shin, Benjamin D. Almquist,",
      "text" : "Doo Sung Lee, and Jae Hyung Park*\nDr. K. Y. Choi, Dr. H. S. Han, J. M. Shin, Prof. D. S. Lee, Prof. J. H. Park School of Chemical Engineering College of Engineering Sungkyunkwan University Suwon 16419, Republic of Korea E-mail: jhpark1@skku.edu Dr. K. Y. Choi, Dr. H. S. Han Natural Product Informatics Research Center Korea Institute of Science and Technology Gangneung 25451, Republic of Korea E. S. Lee, Prof. J. H. Park Department of Health Sciences and Technology SAIHST Sungkyunkwan University Suwon 16419, Republic of Korea Dr. B. D. Almquist Department of Bioengineering Imperial College London SW7 2AZ London, UK Prof. D. S. Lee Theranostic Macromolecules Research Center Sungkyunkwan University Suwon 16419, Republic of Korea\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201803549.\nDOI: 10.1002/adma.201803549\n1. Introduction\nThere has been an exponential growth in nanomaterials research for healthcare applications since Maeda and co-workers first reported the revolutionary concept of the enhanced permeation and retention (EPR) effect, also known as passive targeting.[1,2] Ensuing studies on the EPR effect have suggested that nanomaterials preferentially accumulate through the leaky vasculature in fast-growing, inflamed tissues like tumors.[3–7] This preferential accumulation has grown into a promising strategy for harnessing nanosized carriers (nanocarriers) for targeted delivery of imaging and therapeutic agents to the diseased tissues, and many types of nanocarriers such as liposomes, polymeric self-assemblies, and proteinbased formulations are now available for targeted imaging and therapeutics.[8–15]\nIn addition to designing new forms of nanocarriers, significant effort has devoted into improving their ability to target localized tissues of interest.[12,16,17] Initial efforts focused on camouflaging the nanomaterials with hydrophilic, nonionic polymer chains such as poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA) or polysaccharides, to reduce phagocytic uptake and clearance of nanomaterials from the bloodstream.[18–21] By lowering the rate of removal, the nanocarriers’ circulation half-life is increased, providing additional opportunities to pass through the fenestrated vasculatures and accumulate in the diseased tissues via the EPR effect.[22] This passive accumulation was subsequently improved by active targeting via attachment of antibodies, peptides, or small-molecule ligands onto nanomaterials that specifically target the tissue of interest.[23,24] Despite their attractive ability to accumulate preferentially in local tissue areas of interest, nanomaterials still have ample room for improvement. For imaging or therapeutic payloads to function correctly, they need to be released or dissociated from the nanomaterials at the desired site of action promptly after the nanomaterials accumulate in the diseased tissues.\nRecently, the ability of nanomaterials to respond actively to local microenvironments, to enable spatial and temporal functions, has emerged as a promising strategy for diagnostic and\nThere is a rapidly increasing interest in developing stimuli-responsive nanomaterials for treating a variety of diseases. By enabling the activation of function locally at the sites of interest, it is possible to increase therapeutic efficacy significantly while simultaneously reducing adverse side effects. While there are many sophisticated nanomaterials available, they are often highly complex and not easily transferrable to industrial scales and clinical settings. However, nanomaterials based on hyaluronic acid offer a compelling strategy for reducing their complexity while retaining several desirable benefits such as active targeting and stimuli-responsive degradation. Herein, the basic properties of hyaluronic acid, its binding partners, and natural routes for degradation by hyaluronidases—hyaluronic-aciddegrading enzymes—and oxidative stresses are discussed. Recent advances in designing hyaluronic acid–based, actively targeted, hyaluronidase- or reactive-oxygen-species-responsive nanomaterials for both diagnostic imaging and therapeutic delivery, which go beyond merely the classical targeting of CD44, are summarized.\nStimuli-Responsive Nanomaterials\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (2 of 18)\ntherapeutic delivery.[25–29] These nanocarriers can change their molecular structure, solubility, surface characteristics, shape, and self-association or dissociation behaviors in response to endogenous stimuli such as pH changes,[30–35] different levels of enzymes,[36–39] cellular traction forces,[40] reactive oxygen species (ROS),[41–43] or glutathione[44–47] in diseased tissues or in intracellular compartments. Also, they can respond to exogenous stimuli, such as laser irradiation[45] or temperature changes,[48–50] to generate an off/on activation of imaging or therapeutic function.\nTaken together, it is possible to see that the ideal nanocarriers can circulate in the bloodstream for a prolonged period, accumulate in the target tissues, facilitate internalization by the target cells, and finally activate their desired diagnostic or therapeutic functions at the site of action and in a stimuli-responsive manner. However, it is challenging to simultaneously incorporate these diverse functions into a nanocarrier while still maintaining the nanoscale dimensions that facilitate efficient uptake. Recent progress in chemistry, materials science, and drug-delivery technology has made it possible to devise highly sophisticated nanocarriers with multiple functions; however, in practice nanomaterial design has generally become more and more complicated.\nUnfortunately, the intricate design simultaneously increases the number of synthesis steps and the cost of synthesis, making large-scale synthesis quite challenging when aiming to scale-up the production to industrial settings. Furthermore, the complicated nanomaterial design can make the nanocarrier less biocompatible and increase the difficulty of gaining approval by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for clinical use. Therefore, there is a pressing need to promote a conceptual shift regarding the design of nanocarriers; simple designs carry significant translational potential compared to highly complex designs as long as they meet a necessary number of critical criteria for the nanocarriers. Ideally, this will be achievable with components that are biocompatible, biodegradable, and readily cleared out of the body to maximize the probability of nanocarriers being a safe and effective option in the clinic.\nOne biomaterial that has the potential to provide this simplified approach to design of nanocarrier systems while retaining multifunctionality is hyaluronic acid (HA).[51,52] HA is a negatively charged and nonsulfated glycosaminoglycan composed of repeating disaccharide units of d-glucuronic acid and N-acetyl-d-glucosamine. HA and its derivatives are widely used as injectable hydrogels and biological scaffolds in clinical settings for several decades due to its outstanding biocompatibility, biodegradability, hydrophilicity, and nonimmunogenicity.[53,54] HA is also a well-known ligand for cell surface receptors such as CD44, CD168 (also known as receptor for hyaluronan-mediated motility, RHAMM), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1).[55] Moreover, hyaluronidases (Hyals), HA-degrading enzymes such as Hyal-1, Hyal-2, and PH-20,[56–58] as well as oxidative stresses (OSs) including ROS and reactive nitrogen species (RNS),[59,60] catabolize HA in the human body. Notably, the level of expression of CD44, Hyals, and OSs is highly related to the progression of many types of diseases such as cancer,[57,61–65] rheumatoid arthritis,[66–68] and traumatic brain injury.[69,70]\nGiven the fascinating physicochemical and biological traits, HA now serves as a versatile building block for various nanomaterials.[51] Starting in 1994, Yerushalmi et al. first reported a liposome with HA as a bioadhesive surface ligand for topical drug delivery.[71] Then in 2001, Szoka and coworkers used HA liposomes to facilitate targeted drug delivery via upregulated CD44 receptors on B16F10 murine melanoma\nKi Young Choi is a senior research scientist of the Natural Product Informatics Research Center at Korea Institute of Science and Technology. He received his Ph.D. degree in pharmacy from Kyung Hee University in 2011. Afterwards, he was trained at NIH and MIT as a postdoctoral researcher and at Sungkyunkwan University\nas a research professor. The focus of his current research is the development of diverse nano-biomaterials for healthcare applications. One specific area is the development of nanomaterials based on hyaluronic acid for applications in disease-specific, stimuli-responsive imaging and therapeutics.\nDoo Sung Lee received his Ph.D. in chemical engineering from Advanced Institute of Science and Technology (KAIST) in 1984. He joined the faculty of Sungkyunkwan University (SKKU) in 1984 and has been a director of the Theranostic Macromolecules Research Center (ERC) from 2010. He is a member of the Korean Academy of Science\nand Technology, the National Academy of Engineering of Korea, and was president of the Polymer Society of Korea in 2013. His current research interest focuses on the development of functionalized and biodegradable injectable hydrogels and micelles for controlled drug and protein delivery.\nJae Hyung Park is a professor of the School of Chemical Engineering at Sungkyunkwan University in Korea. He received his Ph.D. degree in materials science and engineering from Gwangju Institute of Science and Technology in 2002. His research focuses on the development of stimuli-sensitive polymeric nanomedicine,\nmultifunctional hybrid nanomaterials, and engineered exosomes for various biomedical applications.\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (3 of 18)\ncells.[72] In their study, the authors loaded the HA liposomes with the anticancer drug doxorubicin (DOX); the targeted, DOXloaded HA liposomes exhibited over 200-fold higher anticancer effects than nontargeted, DOX-loaded liposomes and over 8-fold higher effects than free DOX.\nSince then, researchers have developed a wide variety of CD44-targeted HA nanomaterials for targeted imaging and therapeutics. As illustrated in Figure 1, HA serves as a polymer backbone of self-assembled polymeric micelles, nanoparticles, or nanogels;[73–78] HA is also chemically conjugated or physically complexed onto liposomes, polymeric nanoparticles, or inorganic nanoparticles[53,72,79] as a targeting ligand. Conveniently, due to the high biocompatibility and hydrophilicity of HA, additional hydrophilic polymer chains are generally not required to prolong the circulation time. Also, diseased cells and tissues\ncommonly upregulate specific cell-surface receptors that bind HA, enabling HA-based nanomaterials to target local regions of diseased tissues both actively and passively.[22,51,75]\nIn addition to the ability of HA to facilitate active and passive targeting, researchers have explored the unique catabolism of HA by Hyals and OSs in diseased tissues. Increased levels of Hyals or OSs in diseased tissues often link with the late progression of various diseases such as cancer. Inspired by this disease-specific enhancement in the rate of degradation, HA has rapidly grown as a major component of stimuli-responsive nanomaterials, with Lee and co-workers first reporting the use of environment-responsive HA in 2007.[77] In the study, they demonstrated that hyaluronidases can degrade HA nanogels loaded with siRNA. The following year, the same group developed an activatable nanomaterial based on gold nanoparticles\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (4 of 18)\nconjugated with a fluorescently labeled HA oligomer for Hyaland ROS-responsive tumor imaging.[79]\nDue to these multifunctional benefits, over the past two decades, HA has rapidly become one of the most popular biomaterials for targeted drug delivery. The combination of bioadhesive features via targeting to CD44, RHAMM, or LYVE-1 along with Hyals- and ROS-related degradation of HA has provided a diverse toolset with which to design unique nanocarriers. Since Yerushalmi et al.’ first report of an HA liposome in 2001, there have been over 1000 publications on HA-based nanoparticles for healthcare applications. Among them, ≈300 publications explore HA-based CD44-, RHAMM-, or LYVE-1-targeted nanomaterials. Interestingly, less than ten publications each year from 2000 to 2012 explore CD44-targeted HA nanomaterials, which increases to 39 in 2014 and then 89 in 2016, indicating the rapidly growing interest of researchers in HA-based nanomaterials. Meanwhile, since Lee and co-workers reported the first stimuli-responsive HA nanomaterial in 2007, only 18 articles address the research topic from 2007 to 2011. However, the number of publications increases to 29 in 2014 and 54 in 2016, again demonstrating the rapidly expanding attention of researchers to the unique benefits provided by HA nanomaterials (Figure 2).\nGiven this rapidly increasing interest in HA nanomaterials, there have been several excellent reviews that describe research involving CD44-targeted nanomaterials;[51,80–83] however, there is a lack of reports covering the healthcare applications of HA-based stimuli-responsive nanomaterials. Therefore, our general focus here is on the healthcare applications of HA-based stimuli-responsive nanomaterials along with some fundamental physicochemical and biological attributes of HA. Here, the activation stimuli are limited to hyaluronidases or oxygen stresses that can induce HA-backbone catabolism."
    }, {
      "heading" : "2. Characteristics of Hyaluronic Acid",
      "text" : ""
    }, {
      "heading" : "2.1. Chemical Structure and Physicochemical Properties of HA",
      "text" : "HA is a biocompatible anionic polysaccharide found throughout the human body, including places such as the skin, joint fluid,\nthe umbilical cord, and the vitreous humor.[84–88] The biosynthesis of HA is a highly regulated process; it is synthesized in the Golgi network by HA synthase enzymes (HAS-1, HAS-2, HAS-3). Using uridine diphosphate (UDP) as a substrate, HA synthases alternatively add UDP-α-N-acetyl-d-glucosamine and UDP-α-d-glucuronate to create the HA chain.[85,89] From this process, HA has β-1,3-N-acetyl glucosamine and β-1,4glucuronic acid as repeating units, which facilitate its chemical modification using carboxylic, hydroxyl, and aldehyde end groups. The typical molecular weight of HA ranges from 5 to 20 000 kDa in vivo. The disaccharide repeating unit of HA is ≈1 nm in length, making an HA molecule with 10 000 repeat units ≈10 µm in length, similar to the diameter of a human erythrocyte.[90]\nIn aqueous solution, HA can result in very high viscosity, elasticity, and large hydrodynamic volume in proportion to its molecular weight.[90] Due to its random-coil structure, strong hydrogen bonds, and interaction with water in aqueous conditions, as well as intramolecular interactions, it can demonstrate beneficial shear-thinning behavior. For instance, 1% HA solutions with molecular weights greater than ≈1000 kDa behave like jelly yet flow when pressure is applied, making them amenable to minimally invasive medical applications.[89]"
    }, {
      "heading" : "2.2. HA Binding Proteins: Hyaladherins",
      "text" : "HA is establishing itself as one of the most important biomolecules in vivo due to its diverse biological functionalities including facilitating cell adhesion, cell migration, and extracellular matrix formation, which arise due to specific binding with HA-binding proteins called hyaladherins. In 1972, Hardingham and Muir described proteoglycans from cartilage that specifically bind HA, which they named aggrecans.[91] In 1990, hyaladherins were then reported as being HA-binding proteins.[55] Among hyaladherins, CD44 and LYVE-1 are the most well-described receptors for HA.\nCD44 is a cell-surface protein that plays a vital role in cell–cell interaction, cell adhesion, and migration.[92,93] One of the essential functions of CD44 is its specific binding affinity for HA, which\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (5 of 18)\nimplies the use of CD44 as a facilitator of HA-mediated targeting. The specific binding between HA and CD44 is widely studied, with a motif of two basic amino acids adjoining a seven-aminoacid stretch called B(X7)B of CD44 being essential for specifically binding HA.[94] Another study reported that the amino-terminal of the CD44 domain is mainly responsible for recognizing and binding with three repeating units of HA.[95] This specific binding ability enables HA-based nanomaterials to be effectively taken up by cells, especially in situations such as cancer, which routinely overexpresses CD44. Moreover, activated macrophages overexpress CD44 on their surfaces, positioning HA as a potential targeting moiety for intractable disease therapies.[96]\nAside from CD44, HA-based nanomaterials can target several additional hyaladherins. These include stabilin-2 (HARE), which is overexpressed in atherosclerotic plaques, LYVE-1, which is expressed in lymphatic vessel endothelium, and TSG-6, which is abundant at sites of inflammation.[97–99] By utilizing these different hyaladherins, HA-based materials can be designed that target a wide variety of tissue types and locations for improving the overall efficiency of delivering nanoparticles."
    }, {
      "heading" : "2.3. Enzymatic Degradation of HA by Hyaluronidases",
      "text" : "Degradation of HA is a very fast and frequent process. Although 30% of HA degrades and is replaced with new HA every day, the half-life of HA is dependent on where it is located in the body.[100] For example, HA in the vitreous of the eye has a long half-life of 70 days, whereas HA in the skin has a short half-life of ≈1 day.[101,102] Regardless of the anatomical location, a specific family of enzymes, hyaluronidases, controls the degradation of HA, which directly cleave the β-N-acetyl-d-glucosaminidic bond in the HA chain[103] due to specific structural features of Hyals.[58]\nIn the human body, there are six kinds of Hyal genes including HYAL1, HYAL2, HYAL3, HYAL4, HYAL5, and HYAL6. The six Hyal genes group into two tightly linked clusters\non chromosome regions 3p21.3 (HYAL1, HYAL2, and HYAL3) and 7q31.3 (HYAL4, HYAL5, and HYAL6).[104] Among the various Hyals, Hyal1 and Hyal2 are the major enzymes responsible for hydrolyzing the β-1,4-glycosidic bond from 3-N-acetyl glucosamine and 4-glucuronic acid (Figure 3). Hyal2 breaks the extracellular, CD44-bound high-molecular-weight HA into intermediate fragment molecules that internalize to the endolysosome compartment. In contrast, Hyal1 degrades fragmented HA to oligo hyaluronic acid.[64,105] This degradation of HA by Hyals is an essential and highly regulated process in biological systems.[84] However, in diseases such as cancer and rheumatoid arthritis, the degradation of HA is dysregulated and can be used as an indicator of the progression of the disease.[106,107]\nIn the case of cancer, the degradation of HA by Hyals is highly involved in tumor malignancy, angiogenesis, and metastasis,[61,65,108–111] with elevated levels of Hyals found in various tumor types including head and neck, brain, lung, bladder, and metastatic breast cancer.[62,112–117] In breast cancer, overexpression of Hyal1 is related to the degree of malignancy.[63] Furthermore, HA fragmentation by locally upregulated Hyal1 leads to tumor-cell proliferation, migration, invasion, and angiogenesis in vivo suggesting that it is a critical contributor to the malignant behavior.[118] In prostate cancer, coexpression of Hyal and HA correlates with rapid cancer-cell proliferation, implying that excess synthesis and processing of HA contributes to cancer growth.[119] Therefore, when developing HAbased materials, the relationship between cancer behavior and Hyals needs to be carefully considered.[108]"
    }, {
      "heading" : "2.4. Oxidative Degradation of HA by Reactive Oxygen Species/Reactive Nitrogen Species",
      "text" : "An alternative pathway of HA catabolism is via ROS. ROS can fall into the category of either radical and nonradical ROS. Radical ROS includes superoxide radical (O2−), hydroxyl radical (OH•),\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (6 of 18)\nperoxyl radicals (ROO•), and alkoxyl radicals (RO•), whereas nonradical ROS contain hydrogen peroxide (H2O2), organic peroxide (ROOR′), ozone (O3), and aldehydes (HCOR).[120] Both radical and nonradical ROS such as hydroxyl radical and hydrogen peroxide can induce cleavage of the HA backbone, generating smaller fragments.[60] When the cleavage takes place, HA changes into an intermediate state containing a radical in its molecule.[59] Thermodynamic driving forces then lead to subsequent degradation of the HA backbone (Figure 3).[121]\nIn addition to ROS, RNS degrades HA and separates into radical and nonradical RNS. The representative radical RNS is the NO radical (NO•), and that for nonradical RNS is peroxynitrite (ONOOH).[120] As an example, NO-mediated degradation of HA takes place by the nitrosonium cation (NO+).[122] This process can produce peroxynitrite molecules that can fragment the high-molecular-weight HA.[59] From this fragmentation, radicals formed at the C(1), C(3), or C(4) positions degrade the HA backbone (Figure 3).\nPathological conditions such as rheumatoid arthritis also give rise to increased levels of OS-mediated HA catabolism. Due to the enhanced degradation of HA arising from localized inflammation, there is a significant alteration of the rheological index\nof synovial fluid.[123,124] In joint synovial fluid, increasing levels of inflammation correlate with decreasing viscosity. This phenomenon is highly related to ROS generated by the inflammation, which depolymerizes high-molecular-weight HA, leading to a reduction in the viscosity of the synovial fluid. Therefore, OS has been recognized as an indicator of disease progression, a significant contributor to RA-associated tissue injury,[68] and can be regarded as a promising target when designing nanomaterials for diagnostic imaging and targeted therapy."
    }, {
      "heading" : "3. Stimuli-Responsive Nanomaterials Based on Hyaluronic Acid",
      "text" : ""
    }, {
      "heading" : "3.1. Material Design",
      "text" : "Due to the promise of HA as a multifunctional biopolymer, significant effort has devoted into modifying the structure of HA and designing various HA-based nanomaterials (Figure 1 and Table 1). One strategy for developing self-assembled HA nanoparticles is to modify the backbone or ends of HA chemically to increase the local hydrophobicity;[44,46,73–75,78] both the primary\nAdv. Mater. 2019, 1803549\nTable 1. HA-based nanomaterials.\nDesign Typea) Applicationa) Refs.\nSelf-assembly HA–PTX conjugates Cancer cell treatment [78]\nHA nanogels siRNA delivery [77]\nZn-DPA-labeled HA–CA NPs siRNA delivery [39,125]\nHA–CA NPs Tumor imaging [22,74,75]\nFlt1 peptide–HANPs Pulmonary imaging and therapy [126]\nCe6-conjugated HANPs PDT of activated macrophages [43]\nHA–PLA NPs Sensing bacterial enzymes [127]\nHA–CA NPs Diabetes imaging and therapy [128]\nHA–CA NPs Atherosclerosis imaging and therapy [129]\nHA–CA NPs Atherosclerosis imaging [97]\nHA–CA NPs Rheumatoid arthritis imaging and therapy [130]\nPEGylated HA–CA NPs Colon cancer therapy and imaging [131]\nHA–MTX conjugates Rheumatoid arthritis imaging and therapy [132]\nPhysical complexation PEGylated HA-immobilized GICs siRNA delivery [133]\nHA-covered LbL NPs Drug delivery [134]\nHA–QD conjugates Lymphatic vessel imaging [135]\nHA-immobilized PPy NPs Atherosclerosis imaging and therapy [136]\nHA-covered LbL NPs Multimodal imaging [137]\nChemical conjugation EGF-conjugated HA patches Wound healing and regeneration [138]\nHA-coated NCPs MRI-guided drug delivery [139]\nHA-immobilized mesoporous silica nanocapsule Ultrasound-imaging-guided therapy [140]\nFluorescein-labeled HA-immobilized AuNPs Ischemic brain imaging [141]\nRB-labeled HA–UCNPs Rheumatoid arthritis imaging [142]\nHA-coated AgNPs X-ray CT and SPECT imaging [143]\na)Abbreviations: AgNP: silver nanoparticle; AuNP: gold nanoparticle; CA: 5-β-cholanic acid; Ce6: chlorin e6; EGF: epidermal growth factor; Flt1: fms-related tyrosine kinase-1; GIC: gold-installed complex; LbL: layer-by-layer; NCP: nanoscale coordination polymer; NP: nanoparticle; PEG: poly(ethylene glycol); PLA: poly(lactic acid); PPy: polypyrrole; PTX: paclitaxel; QD: quantum dot; RB: Rhodamine B; siRNA: small interfering RNA; CT: X-ray computed tomography; SPECT: single-photon-emission computed tomography; Zn-DPA: Zn(II)-dipicolyamine.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (7 of 18)\nhydroxyl groups at the C6 position on the HA and the carboxyl groups are easily modified due to their relatively high reactivity. Using this strategy, amphiphilic HA conjugates composed of HA and hydrophobic moieties such as fatty acids, bile acids, or hydrophobic imaging or therapeutic agents such as paclitaxel (PTX) or chlorin e6 (Ce6) are possible.[43,73–75,78]\nFor example, amphiphilic HA–PTX conjugates self-assemble to form nanosized spherical micelles in aqueous solution.[78] PTX conjugated to the HA backbone via an acid-cleavable ester linkage enables pH-dependent PTX release in the slightly acidic tumor microenvironment, resulting in an enhanced cytotoxic effect to tumor cells. Similarly, HA–5β-cholanic acid (CA) conjugates also self-assemble into NPs in aqueous conditions, partitioning anticancer drugs to the hydrophobic core.[74,75] To prepare the conjugates, amine-functionalized CA is chemically conjugated onto the HA backbone by the formation of stable amide bonds via EDC-mediated crosslinking. In other work, HA labeled with fluorescent dyes or radioisotopes has enabled noninvasive PET imaging of atherosclerosis-associated inflammation via selective targeting of plaque-associated macrophages.[129] Here, oligomeric amine-functionalized HA enables modification with cholanic ester and subsequent formation of nanoparticles.\nA similar strategy for preparing HA-based nanomaterials is to conjugate HA chemically onto nanomaterials. Since HA has available functional groups such as hydroxyl, aldehyde, and carboxylic acid groups for chemical modifications, a diverse array of HA-based nanomaterials is possible for biomedical applications.[11,144,145] Recent studies have explored the use of HA as a coating material on the surface of silver nanoparticles (AgNPs), upconversion nanoparticles (UCNPs), gold nanoparticles (AuNPs), and mesoporous silica nanoparticles (MSNPs) for targeted imaging and therapy.[139,141–143] For instance, a rapid and straightforward chemical-reduction method enables the synthesis of HA-coated AgNPs for X-ray computed tomography and singlephoton-emission computed tomography (SPECT) imaging.[143] By reacting the carboxyl groups on the HA backbone with AgNO3 in the presence of sodium borohydride, the Ag+ complexes rapidly reduce into spherical, ultrasmall AgNPs. This chemicalreduction approach enables the creation of monodispersed HAcoated AgNP with long-term stability and low cytotoxicity.\nIn addition to chemically modifying HA to create HA-based nanomaterials, the intrinsic negative charge of HA can be used to electrostatically complex HA with complementary polyions. Suitable complimentary polyions are quite diverse and include a variety of polysaccharides, polymers, proteins, and nanoparticles. For instance, HA readily complexes with positively charged organic nanoparticles based on PEI[133] and polypyrrole (PPy)[136] and inorganic nanoparticle quantum dots (QDs)[135] for imaging sites of inflammation via effective targeting of CD44. In addition to just coating the surface of nanoparticles with HA, the versatile layer-by-layer (LbL) process enables the creation of multifunctional HA nanomaterials. LbL HA-nanomaterials generally consist of a functional inner core, a multilayered polyelectrolyte shell, and an exterior tumor-targeting HA layer. In one study, sequential adsorption and centrifugation in aqueous HA and poly(l-lysine) solutions produced HA-based LbL nanoparticles.[134] Due to the assembly process relying on the balance of pH-sensitive positive and negative charges, the HA–LbL NPs\ndemonstrate a pH-dependent structural transition at hypoxic tumor pH, where swelling, the loss of the anionic HA charge, and a decreased surface charge facilitates enhanced tumor penetration and cellular uptake in vitro."
    }, {
      "heading" : "3.2. Stimuli-Responsive Nanomaterials for Biomedical Imaging",
      "text" : "The inherent degradability of HA has led to a diverse array of HA nanomaterials for in vivo imaging that can facilitate the diagnosis of disease, monitoring responses to drug treatment, and molecular imaging of either Hyal or ROS (Figure 4). Imaging tools such as optical fluorescence, magnetic resonance imaging (MRI), photoacoustic imaging (PA), computed tomography (CT), positron-emission tomography (PET), SPECT, and upconversion luminescence (UCL) are all amenable to HAbased nanomaterials (Table 2)."
    }, {
      "heading" : "3.2.1. Hyaluronidase-Sensitive HA Nanoparticles",
      "text" : "HA nanoparticles that self-assemble from amphiphilic HA conjugates are promising systems for in vivo imaging and therapy. Conveniently, self-assembling HA nanoparticles preferentially accumulate in many tumors via their intrinsic ability to bind overexpressed CD44 receptors. Following CD44-mediated targeting and endocytosis, HA NPs can be designed to degrade in the tissues via Hyals. In one of the first demonstrations, fluorescently labeled nanoparticles self-assembled from HA–CA enabled tumor-specific optical imaging via cyanine 5.5 (Cy5.5).[74,75] Following concentration at the tumor site, the near-infrared fluorescence (NIRF) signal facilitated active tumor detection.[131] Subsequent studies utilized the amphiphilicity of the HACA to encapsulate hydrophobic imaging and/or therapeutic agents into the core of the nanoparticles. By taking advantage of the rapid degradation by Hyals, this strategy enabled a rapid burst-release of imaging and/or therapeutic agents at the local diseased tissue.[38,39,125,155]\nIn addition to optical imaging, photoacoustic imaging is addressable using HA nanoparticles. In one study, HA NPs loaded with copper sulfide (CuS) and labeled with Cy5.5 (HANPCs) enabled dual optical and photoacoustic imaging of SCC7 tumors in vivo (Figure 5).[152]\nIn this system, CuS quenches the fluorescence signals from the Cy5.5 on the HANPCs, but when the nanoparticles degrade due to Hyals at the target site, the strong fluorescence signal recovers. Conveniently, CuS also facilitates optical/PA-imageguided photothermal therapy (PTT). Based on the strong light absorbance of CuS, the authors implemented image-guided PTT 12 h after injection, which corresponded to the time at which there was the maximum concentration of HANPCs within the tumors.\nAttaching HA to the surface of materials can also be used to simultaneously improve multiple properties such as solubility, biocompatibility, and active targeting ability. For instance, researchers demonstrated a simple one-step formulation technique to modify single-walled carbon nanotubes (SWCNTs) with an HA–5β-cholanic acid conjugate (HAC) for various imaging application via PA, fluorescence, and PET (Figure 6).[151]\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (8 of 18)\nFor fluorescence imaging, researchers labeled HA with fluoresceinamine (FA) and Cy5.5 (HAdye) followed by cholanic acid conjugation. The high optical absorbance of the SWCNTs resulted in quenching of the fluorescence signals from the HAdye; however, exposure of the HA nanotube (HA-NT) formulations to increasing concentrations of Hyals resulted in the recovery of strong fluorescence signals. In addition, the researchers demonstrated in vivo PET, fluorescence, and PA imaging using 64Cu-labeled HA-NTs and HACy5.5-NTs in tumor mouse models. Interestingly, fluorescence signals were significantly quenched throughout the mice, including at the tumor site, for 24 h before activation at the tumor site. This delay in fluorescence signal compared to PET or PA imaging provided a straightforward method for observing the localized degradation kinetics by Hyals in tumor tissues."
    }, {
      "heading" : "3.2.2. ROS-Sensitive HA Nanoparticles",
      "text" : "ROS play an important role in biological events ranging from cell homeostasis to proliferation to cell death, while also maintaining a low level of expression in normal physiological conditions. However, many diseases lead to localized overexpression on ROS, enhancing the degradation of HA via the preferential cleavage of β-(1→4) glycosidic bonds. This elevated degradation at sites of the disease has catalyzed many studies exploring the potential of using HA as a degradable trigger for activatable imaging.[43,79,141,142,154] In one study, researchers used AuNPs functionalized with NIRF-dye-labeled oligomeric HA (HHAuNPs) for in vivo detection of rheumatoid arthritis (RA) or cancer, which are well known for upregulating ROS or Hyals, respectively.[79] The\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (9 of 18)\nNIRF signals from the dye conjugated on the AuNPs quenches near the nanoparticle surface due to nanosurface energy transfer (NSET); however, the fluorescence recovers following degradation of the oligomeric HA linker between the NIRF dye and AuNPs due to either ROS or Hyals. The fluorescence of HHAuNPs increased with increasing concentration of ROS and Hyal, revealing the dosage-dependent detection ability of the HHAuNPs (Figure 7). To demonstrate in vivo functionality, the HHAuNPs were injected intra-articularly, intratumorally, and intravenously into both RA and tumor models. In both disease models, the HHAuNPs preferentially accumulated in arthritic joints, digits, or tumors via the EPR effect and the CD44-receptor interaction of HA, followed by recovery of the fluorescence signals.\nIn other research, HHAuNPs facilitated the early detection of brain stroke.[141] Following the inducement of ischemic brain\nstroke via middle cerebral artery occlusion (MCAO), HHAuNPs were injected locally into the ischemic brain. The ex vivo fluorescence intensity reached its maximum 24 h after MCAO, implying that brain damage progressed for up to 24 h after the occlusion (Figure 7). The authors also noted that by using the HHAuNPs, they could detect the acute and sub-acute stages of the ischemic brain-stroke region, which developed at the infarct area within 4 h.\nIn other work, researchers developed ROS-responsive macrophage-targeted theranostic nanoparticles (MacTNPs) composed of photosensitizer Ce6–HA conjugates for targeted NIR imaging and photodynamic therapy (PDT) of activated macrophage-related disease such as atherosclerosis.[43] Initially, the MacTNPs are nonfluorescent and nonphototoxic due to a self-quenching effect between the conjugated Ce6 molecules, but they became fluorescent and highly phototoxic in high\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (10 of 18)\nROS conditions. In addition to being sensitive to ROS, the MacTNP exhibited a particularly sensitive peroxynitrite-responsive recovery of fluorescence and singlet oxygen generation (SOG). Interestingly, the authors noted that the effect of Hyals on the fluorescence recovery of the MacTNPs was negligible despite Hyals cleaving HA at a rate comparable to peroxynitrite. The ability to target macrophages was determined via live cell imaging with activated RAW 264.7 cells, while recovery of Ce6 fluorescence was evaluated by FACS analysis and confocal fluorescence microscopy in normal human dermal fibroblasts (HDFs), and nonactivated and activated RAW 264.7 cells. Taken together, these data revealed that the MacTNPs were endocytosed by activated macrophages, followed by the release of Ce6 molecules and subsequent fluorescence recovery. Finally, subsequent laser irradiation verified the possibility of using MacTNPs as potential agents for PDT.\nOther research has explored the use of upconversion luminescence imaging for the detection of ROS in vitro and for diagnosis of RA in vivo.[156] UCNPs, which convert nearinfrared radiation to visible light, have emerged as promising optical probes due to their unique intrinsic properties including low photobleaching, no autofluorescence, and deep lightpenetration depth compared to conventional fluorescence dyes. In one study, researchers developed luminescent resonance energy transfer (LRET)-based β-NaFY4: 18%Yb/2%Er UCNPs conjugated with rhodamine-B-labeled HA (HAR–UCNPs). In the absence of ROS, the UCNPs act as an energy donor, exciting the rhodamine B, resulting in a fluorescence signal from the dye. Treatment with ROS cleaves the HA, liberating the rhodamine B and stopping the LRET process but enabling UCL emission. In vitro experiments indicated that the HAR– UCNPs were sensitive to the concentration of ROS, suggesting that the probes may be suitable for detecting ROS levels in vivo (Figure 8). This in vivo ability was then investigated using an RA mice model, enabling the monitoring of the early response to treatment with antirheumatic drugs such as MTX.\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (11 of 18)"
    }, {
      "heading" : "3.3. Hyaluronidase-Sensitive HA Nanoparticles for Drug and Gene Delivery",
      "text" : "To achieve the optimal therapeutic effect of nanomaterials, they must facilitate the delivery of therapeutics to the desired site of action. For example, siRNAs need to reach the cytoplasm of cells, where they can integrate into the RISC complex and silence the translation of the target mRNA.[157] On the other hand, chemotherapeutics such as doxorubicin are most effective when localized inside the nucleus, where they interfere\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (12 of 18)\nwith DNA replication.[158] Therefore, it is important to consider not only intracellular versus extracellular delivery, but also the final intracellular location when engineering nanomaterials for customized drug delivery.\nIn one study, researchers developed Hyal-responsive nanocarriers for cancer therapeutics, which were composed of amphiphilic PEGylated-HA conjugates (P-HANPs) and hydrophobic drugs (DOX as a fluorescent model drug or camptothecin (CPT) as a cytotoxic anticancer drug) (Figure 9).[38] The P-HANPs showed cancer cell–specific uptake in vitro via receptor-mediated endocytosis. In vivo biodistribution studies indicated that the CPT–P-HANPs effectively accumulated in tumor tissue due to their prolonged circulation and specific binding to upregulated expression of CD44 on tumor cells. Trapping DOX and CPT in the hydrophobic core of the P-HANPs suppressed the fluorescence signals of the DOX and the therapeutic activity of the CPT. However, when incubated with Hyal or tumor lysates, the P-HANPs released the DOX and CPT, recovering the fluorescence signals from the DOX and the potent anticancer activity of the CPT. By taking advantage of both the HA-mediated active targeting and Hyal-responsive, site-specific drug release in tumor tissues, the P-HANPs loaded with CPT elicited significant antitumor activity in MDA-MB231 mouse tumor models with minimal adverse side effects.\nIn addition to chemotherapy, HA-based nanomaterials are useful for targeted photodynamic therapy and/or photothermal therapy. Recently, researchers reported biostable, photoactivatable hybrid nanomaterials based on a gold-nanoclustered HA nanoassembly (GNc-HyNA) for photothermally boosted photodynamic tumor ablation (Figure 10).[45]\nIn this study, nanoassemblies of amphiphilic nanoassemblies of amphiphilic HA-polycaprolactone (Hy–PCL) conjugates were prepared as a polymeric reducing agent, which facilitated the simultaneous formation of gold nanoclusters and the loading of hydrophobic verteporfin (Vp). In the structure, the\nhydrophobic PCL core acts as a reservoir for the hydrophobic PDT agent. Meanwhile, the HA brush worked as an active targeting ligand to facilitate CD44-mediated tumor targeting. Importantly, tertiary amines were introduced onto the HA to serve as a reducing moiety and promote the formation of a gold shell. Due to the inert gold shell and self-assembled structure, Vp-encapsulated GNc-HyNA (Vp-GNc-HyNA) showed robust stability in the bloodstream. While the gold nanoclusters covering the surface of the nano assemblies resulted in quenching of the photophysical and photochemical properties of Vp-GNcHyNA, the PDT effect of Vp-GNc-HyNA was addressable via laser-induced photothermal activation under 808 nm laser irradiation. However, the full functionality recovered far more rapidly over time in cancer cells due to high Hyal and glutathione concentration. Notably, a sequential PTT and PDT laser-treated group successfully suppressed tumor growth in an MDA-MB231 orthotopic breast tumor model, resulting in complete tumor ablation with 100% survival rate and skin regeneration at 50 days post-treatment. In the end, these results robustly demonstrated that HA/gold-nanocluster hybrid nanomaterials are employable as both potent PTT agents and photothermally activatable smart PDT nanoformulations.\nIn addition to the delivery of small molecules for anticancer therapies, HA NPs are also promising carriers of nucleic acids for treating drug-resistant tumor cells (Figure 11).[39] In one study, researchers developed a versatile RNAi nanoplatform using tumor-targeting and pH-responsive nanoformulas (NFs). The authors modified the backbone of HA with an artificial RNA receptor, Zn(II)-DPA, followed by further modification with a calcium phosphate (CaP) layer via in situ mineralization. These NFs readily complexed with a variety of RNAi agents in physiological conditions, in turn protecting siRNAs from enzymatic degradation. However, an acidic environment disrupted the NFs and released the RNAs into the cytosol of cancer cells following escape from the endosomes. By coloading the NFs\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (13 of 18)\nAdv. Mater. 2019, 1803549\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (14 of 18)\nAdv. Mater. 2019, 1803549\nwith DOX and siRNA targeting multidrug resistance 1 protein, the NFs enabled sensitization of drug-resistant OVCAR8/ADR cells and suppression of tumor growth in vivo.\nTaken together, HA-based NPs can be utilized for diseases including various kinds of cancer,[159–161] RA,[132,162,163] and diabetes,[128] as carriers for chemotherapy (CHT),[164–166] photodynamic therapy,[155,167] and photothermal therapy,[152,160] along with carriers for biologics such as siRNA[168–170] and applications in immunotherapy (IMT) (Table 3).[171] In the end, these examples demonstrate the diverse possibilities available by using HA-based NPs as actively targeted carriers and/or triggered delivery systems in response to Hyal overexpression at localized sites of disease."
    }, {
      "heading" : "4. Conclusion and Future Perspectives",
      "text" : "Over the past two decades, HA has demonstrated great promise for healthcare applications given its attractive physicochemical and biological features—excellent hydrophilicity, biocompatibility, nonimmunogenicity, strong interaction with hyaladherins, receptor-mediated endocytosis, and catabolism by Hyals and OS. This unique combination of intrinsic attributes of HA enables researchers to construct simple, yet genuinely multifunctional nanostructures, facilitating i) prolonged circu-\nlation in the bloodstream to increase passive accumulation in diseased tissues through leaky blood vessels, ii) active targeting to specific cell surface receptor proteins of interest, iii) internalization into the target cells via receptor-mediated endocytosis, and iv) burst release of imaging or therapeutic agents and activation of their functions in response to Hyals or OS at the disease site.\nUnlike other types of multifunctional nanomaterials with highly sophisticated structures that necessitate a large number of components, HA nanomaterials require a minimal amount of building blocks—HA as a hydrophilic polymer backbone or outer shell, and hydrophobic moieties or nanoparticles to serve as the nanomaterial’s core. Without additional hydrophilic stealth polymer and active targeting ligands, HA nanomaterials both passively and actively target tissues displaying overexpression of hyaladherins. Furthermore, the inherent degradability of HA gives rise to stimuli-responsive activation of the desired functions spatially and temporally. Although in vivo studies using HA nanomaterials have shown preferential accumulation in the liver due to the presence of HA receptors in liver endothelial cells, strategies such as PEGylation may provide a method to overcome this unspecified liver uptake. For instance, reports have demonstrated a reduced uptake in the liver and higher tumor targetability of PEGylated HA nanomaterials after intravenous injection in vivo.[22,38,155,176] However,\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (15 of 18)\nAdv. Mater. 2019, 1803549\nit is necessary to carefully consider the density of PEG on the surface of HA nanomaterials to minimize the decrease of the targeting affinity of HA while simultaneously maximizing the therapeutic effect.\nSince the first reports of CD44-targeted HA liposomes in 2001,[72] a vast amount of effort has devoted into using HA-mediated CD44-targeting for applications in disease imaging and drug delivery. This led to the first reports of stimuli-responsive HA nanomaterials that release payloads in response to HA-degrading enzymes and oxidative stresses to activate their diagnostic or therapeutic functions in 2007 and 2008.[77,79] Since then, the stimuli-responsive functionality of HA nanomaterials has emerged as an effective way to improve the efficacy of targeted drug delivery. Going forward, the simple structure and the easy fabrication process for HA-based nanomaterials may increase the possibility of successful translation to the clinic. Recently, HA nanoformulations, such as hyaluronic-acid–irinotecan, hyaluronicacid–DOX, and hyaluronic-acid–5FU, have been developed by Alchemia in Australia and tested in phase-I, II, and III clinical trials. Although the developments for specific types of cancer are currently on hold because of the unsatisfactory results, researchers are continuously developing new HA-based nanomaterials with various types of therapeutics to generate seed data for potential translation to the clinic for many diseases. In this regard, we are confident that the unique advantages provided by HA nanomaterials will justify the development of additional HA-based nanomaterials for future clinical trials.\nOverall, HA-based nanomaterials provide tremendous potential for targeted imaging and therapy of many diseases. This potential has resulted in an exponential increase in research publications over the last decade, indicating rapid growth in interest surrounding applications of this unique biomaterial. For this promising field to continue its rapid progression, an additional focus is needed regarding the development, characterization, and optimization of simple, yet powerful multifunctional systems. This new research along with other recent research progress then needs expanding on to include a range of parameters and concerns such as manufacturability, toxicity, pharmacodynamics, and biodistribution. In doing so, there is a significant opportunity to take this unique biomaterial from the bench to the bedside and make a meaningful impact clinically with rationally designed and active HA nanomaterials."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was financially supported by the Korea Institute of Science and Technology (KIST) Intramural Research Grant, the Basic Science Research Programs (2015R1A6A3A04059033, 20100027955, and 2018R1A2B3006080) of the National Research Foundation (NRF), and the Technology Innovation Program (10079925) of MOTIE, Republic of Korea. The authors thank the input of Hwayoung Lee for illustrations.\nConflict of Interest The authors declare no conflict of interest.\nKeywords hyaluronic acid, hyaluronidase, oxidative stress, reactive oxygen species, stimuli-responsive nanomaterials\nReceived: June 4, 2018 Revised: December 27, 2018\nPublished online:\n[1] K. Iwai, H. Maeda, T. Konno, Cancer Res. 1984, 44, 2115. [2] Y. Matsumura, H. Maeda, Cancer Res. 1986, 46, 6387. [3] H. Maeda, L. W. Seymour, Y. Miyamoto, Bioconjugate Chem. 1992,\n3, 351. [4] H. Maeda, Adv. Enzyme Regul. 2001, 41, 189. [5] H. Maeda, G. Y. Bharate, J. Daruwalla, Eur. J. Pharm. Biopharm.\n2009, 71, 409. [6] H. Maeda, Bioconjugate Chem. 2010, 21, 797. [7] H. Maeda, Y. Matsumura, Adv. Drug Delivery Rev. 2011, 63, 129. [8] M. Ferrari, Nat. Rev. Cancer 2005, 5, 161. [9] R. Duncan, Nat. Rev. Cancer 2006, 6, 688.\n[10] M. E. Davis, Z. G. Chen, D. M. Shin, Nat. Rev. Drug Discovery 2008, 7, 771. [11] R. A. Petros, J. M. DeSimone, Nat. Rev. Drug Discovery 2010, 9, 615. [12] F. M. Kievit, M. Zhang, Adv. Mater. 2011, 23, H217. [13] M. Elsabahy, K. L. Wooley, Chem. Soc. Rev. 2012, 41, 2545. [14] J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, Nat. Rev. Cancer\n2017, 17, 20. [15] V. P. Torchilin, Adv. Drug Delivery Rev. 2006, 58, 1532. [16] N. Nishiyama, Nat. Nanotechnol. 2007, 2, 203. [17] E. Blanco, H. Shen, M. Ferrari, Nat. Biotechnol. 2015, 33, 941. [18] S. M. Moghimi, A. C. Hunter, J. C. Murray, Pharmacol. Rev. 2001,\n53, 283. [19] D. E. Owens III, N. A. Peppas, Int. J. Pharm. 2006, 307, 93. [20] F. Alexis, E. Pridgen, L. K. Molnar, O. C. Farokhzad, Mol. Pharmaceutics\n2008, 5, 505. [21] S. M. Moghimi, J. Szebeni, Prog. Lipid Res. 2003, 42, 463. [22] K. Y. Choi, K. H. Min, H. Y. Yoon, K. Kim, J. H. Park, I. C. Kwon,\nK. Choi, S. Y. Jeong, Biomaterials 2011, 32, 1880. [23] J. D. Byrne, T. Betancourt, L. Brannon-Peppas, Adv. Drug Delivery\nRev. 2008, 60, 1615. [24] N. Bertrand, J. Wu, X. Xu, N. Kamaly, O. C. Farokhzad, Adv. Drug\nDelivery Rev. 2014, 66, 2. [25] K. Park, S. Lee, E. Kang, K. Kim, K. Choi, I. C. Kwon, Adv. Funct.\nMater. 2009, 19, 1553. [26] S. Lee, K. Park, K. Kim, K. Choi, I. C. Kwon, Chem. Commun. 2008,\n4250. [27] S. Ganta, H. Devalapally, A. Shahiwala, M. Amiji, J. Controlled\nRelease 2008, 126, 187. [28] M. A. Stuart, W. T. Huck, J. Genzer, M. Muller, C. Ober, M. Stamm,\nG. B. Sukhorukov, I. Szleifer, V. V. Tsukruk, M. Urban, F. Winnik, S. Zauscher, I. Luzinov, S. Minko, Nat. Mater. 2010, 9, 101. [29] A. Stejskalova, M. T. Kiani, B. D. Almquist, Exp. Biol. Med. 2016, 241, 1127. [30] J. Ko, K. Park, Y. S. Kim, M. S. Kim, J. K. Han, K. Kim, R. W. Park, I. S. Kim, H. K. Song, D. S. Lee, I. C. Kwon, J. Controlled Release 2007, 123, 109. [31] E. S. Lee, Z. Gao, D. Kim, K. Park, I. C. Kwon, Y. H. Bae, J. Controlled Release 2008, 129, 228. [32] K. H. Min, J.-H. Kim, S. M. Bae, H. Shin, M. S. Kim, S. Park, H. Lee, R.-W. Park, I.-S. Kim, K. Kim, J. Controlled Release 2010, 144, 259. [33] E. S. Lee, K. Na, Y. H. Bae, Nano Lett. 2005, 5, 325.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (16 of 18)\nAdv. Mater. 2019, 1803549\n[34] J. Y. Ko, S. Park, H. Lee, H. Koo, M. S. Kim, K. Choi, I. C. Kwon, S. Y. Jeong, K. Kim, D. S. Lee, Small 2010, 6, 2539. [35] G. Yang, L. Xu, J. Xu, R. Zhang, G. Song, Y. Chao, L. Feng, F. Han, Z. Dong, B. Li, Z. Liu, Nano Lett. 2018, 18, 2475. [36] S. Lee, E. J. Cha, K. Park, S. Y. Lee, J. K. Hong, I. C. Sun, S. Y. Kim, K. Choi, I. C. Kwon, K. Kim, C. H. Ahn, Angew. Chem., Int. Ed. 2008, 47, 2804. [37] S. Lee, J. H. Ryu, K. Park, A. Lee, S. Y. Lee, I. C. Youn, C. H. Ahn, S. M. Yoon, S. J. Myung, D. H. Moon, X. Chen, K. Choi, I. C. Kwon, K. Kim, Nano Lett. 2009, 9, 4412. [38] K. Y. Choi, H. Y. Yoon, J.-H. Kim, S. M. Bae, R.-W. Park, Y. M. Kang, I.-S. Kim, I. C. Kwon, K. Choi, S. Y. Jeong, K. Kim, J. H. Park, ACS Nano 2011, 5, 8591. [39] K. Y. Choi, O. F. Silvestre, X. Huang, K. H. Min, G. P. Howard, N. Hida, A. J. Jin, N. Carvajal, S. W. Lee, J.-I. Hong, X. Chen, ACS Nano 2014, 8, 4559. [40] A. Stejskalová, N. Oliva, F. J. England, B. D. Almquist, Adv. Mater. 2019, https://doi.org/10.1002/adma.201806380. [41] Z. Yang, Y. Dai, C. Yin, Q. Fan, W. Zhang, J. Song, G. Yu, W. Tang, W. Fan, B. C. Yung, J. Li, X. Li, X. Li, Y. Tang, W. Huang, J. Song, X. Chen, Adv. Mater.30, 2018, 1707509. [42] V. G. Deepagan, S. Kwon, D. G. You, V. Q. Nguyen, W. Um, H. Ko, H. Lee, D. G. Jo, Y. M. Kang, J. H. Park, Biomaterials 2016, 103, 56. [43] H. Kim, Y. Kim, I.-H. Kim, K. Kim, Y. Choi, Theranostics 2014, 4, 1. [44] H. S. Han, K. Y. Choi, H. Ko, J. Jeon, G. Saravanakumar, Y. D. Suh,\nD. S. Lee, J. H. Park, J. Controlled Release 2015, 200, 158. [45] H. S. Han, K. Y. Choi, H. Lee, M. Lee, J. Y. An, S. Shin, S. Kwon,\nD. S. Lee, J. H. Park, ACS Nano 2016, 10, 10858. [46] H. S. Han, T. Thambi, K. Y. Choi, S. Son, H. Ko, M. C. Lee, D.-G. Jo,\nY. S. Chae, Y. M. Kang, J. Y. Lee, J. H. Park, Biomacromolecules 2015, 16, 447. [47] A. N. Koo, H. J. Lee, S. E. Kim, J. H. Chang, C. Park, C. Kim, J. H. Park, S. C. Lee, Chem. Commun. 2008, 6570. [48] S. Limmer, J. Hahn, R. Schmidt, K. Wachholz, A. Zengerle, K. Lechner, H. Eibl, R. D. Issels, M. Hossann, L. H. Lindner, Pharm. Res. 2014, 31, 2276. [49] L. Li, T. L. ten Hagen, M. Hossann, R. Suss, G. C. van Rhoon, A. M. Eggermont, D. Haemmerich, G. A. Koning, J. Controlled Release 2013, 168, 142. [50] K. Kono, Adv. Drug Delivery Rev. 2001, 53, 307. [51] K. Y. Choi, G. Saravanakumar, J. H. Park, K. Park, Colloids Surf., B\n2012, 99, 82. [52] B. P. Toole, Nat. Rev. Cancer 2004, 4, 528. [53] H. Knopf-Marques, M. Pravda, L. Wolfova, V. Velebny, P. Schaaf,\nN. E. Vrana, P. Lavalle, Adv. Healthcare Mater. 2016, 5, 2841. [54] J. A. Burdick, G. D. Prestwich, Adv. Mater. 2011, 23, H41. [55] B. Toole, Curr. Opin. Cell Biol. 1990, 2, 839. [56] R. Stern, Eur. J. Cell Biol. 2004, 83, 317. [57] R. Stern, Semin. Cancer Biol. 2008, 18, 275. [58] R. Stern, M. J. Jedrzejas, Chem. Rev. 2006, 106, 818. [59] L. Soltes, R. Mendichi, G. Kogan, J. Schiller, M. Stankovska,\nJ. Arnhold, Biomacromolecules 2006, 7, 659. [60] J. Duan, D. L. Kasper, Glycobiology 2011, 21, 401. [61] A. Schmaus, J. P. Sleeman, Glycobiology 2015, 25, 258. [62] P. Bertrand, N. Girard, C. Duval, J. d’Anjou, C. Chauzy,\nJ. F. Ménard, B. Delpech, Int. J. Cancer 1997, 73, 327. [63] J. X. Tan, X. Y. Wang, H. Y. Li, X. L. Su, L. Wang, L. Ran, K. Zheng,\nG. S. Ren, Int. J. Cancer 2011, 128, 1303. [64] L. Y. Bourguignon, P. A. Singleton, F. Diedrich, R. Stern, E. Gilad,\nJ. Biol. Chem. 2004, 279, 26991. [65] D. Liu, E. Pearlman, E. Diaconu, K. Guo, H. Mori, T. Haqqi,\nS. Markowitz, J. Willson, M. S. Sy, Proc. Natl. Acad. Sci. USA 1996, 93, 7832. [66] M. Farr, K. Garvey, A. M. Bold, M. J. Kendall, P. A. Bacon, Clin. Exp. Rheumatol. 1985, 3, 99.\n[67] H. M. Khojah, S. Ahmed, M. S. Abdel-Rahman, A. B. Hamza, Free Radical Biol. Med. 2016, 97, 285. [68] K. Bauerova, A. Bezek, Gen. Physiol. Biophys. 1999, 1815. [69] S. Plantman, NeuroReport 2012, 23, 647. [70] A. Lipponen, J. Paananen, N. Puhakka, A. Pitkanen, Sci. Rep. 2016,\n6, 31570. [71] N. Yerushalmi, A. Arad, R. Margalit, Arch. Biochem. Biophys. 1994,\n313, 267. [72] R. E. Eliaz, F. C. Szoka Jr., Cancer Res. 2001, 61, 2592. [73] K. Y. Choi, S. Lee, K. Park, K. Kim, J. H. Park, I. C. Kwon, S. Y. Jeong,\nJ. Phys. Chem. Solids 2008, 69, 1591. [74] K. Y. Choi, K. H. Min, J. H. Na, K. Choi, K. Kim, J. H. Park,\nI. C. Kwon, S. Y. Jeong, J. Mater. Chem. 2009, 19, 4102. [75] K. Y. Choi, H. Chung, K. H. Min, H. Y. Yoon, K. Kim, J. H. Park,\nI. C. Kwon, S. Y. Jeong, Biomaterials 2010, 31, 106. [76] C. Yang, X. Wang, X. Yao, Y. Zhang, W. Wu, X. Jiang, J. Controlled\nRelease 2015, 205, 206. [77] H. Lee, H. Mok, S. Lee, Y. K. Oh, T. G. Park, J. Controlled Release\n2007, 119, 245. [78] H. Lee, K. Lee, T. G. Park, Bioconjugate Chem. 2008, 19, 1319. [79] H. Lee, K. Lee, I. K. Kim, T. G. Park, Biomaterials 2008, 29, 4709. [80] J. M. Wickens, H. O. Alsaab, P. Kesharwani, K. Bhise, M. Amin,\nR. K. Tekade, U. Gupta, A. K. Iyer, Drug Discovery Today 2017, 22, 665. [81] S. S. Skandalis, C. Gialeli, A. D. Theocharis, N. K. Karamanos,\nAdv. Cancer Res. 2014, 123, 277. [82] D. A. Ossipov, Expert Opin. Drug Delivery 2010, 7, 681. [83] A. Cadete, M. J. Alonso, Nanomedicine 2016, 11, 2341. [84] E. Papakonstantinou, M. Roth, G. Karakiulakis, Derm-Endocrinol.\n2012, 4, 253. [85] J. Y. Lee, A. P. Spicer, Curr. Opin. Cell Biol. 2000, 12, 581. [86] M. M. Temple-Wong, S. Ren, P. Quach, B. C. Hansen, A. C. Chen,\nA. Hasegawa, D. D. D’Lima, J. Koziol, K. Masuda, M. K. Lotz, R. L. Sah, Arthritis Res. Ther. 2016, 18, 18. [87] Z. Hadidian, N. W. Pirie, Biochem. J. 1948, 42, 260. [88] J. Sebag, E. Balazs, Invest. Ophthalmol. Visual Sci. 1989, 30, 1867. [89] J. Necas, L. Bartosikova, P. Brauner, J. Kolar, Vet. Med. 2008, 53,\n397. [90] M. K. Cowman, S. Matsuoka, Carbohydr. Res. 2005, 340, 791. [91] T. E. Hardingham, H. Muir, Biochim. Biophys. Acta, Gen. Subj.\n1972, 279, 401. [92] A. Aruffo, I. Stamenkovic, M. Melnick, C. B. Underhill, B. Seed,\nCell 1990, 61, 1303. [93] L. Y. Bourguignon, M. Ramez, E. Gilad, P. A. Singleton, M.-Q. Man,\nD. A. Crumrine, P. M. Elias, K. R. Feingold, J. Invest. Dermatol. 2006, 126, 1356. [94] B. Yang, B. L. Yang, R. C. Savani, E. A. Turley, EMBO J. 1994, 13, 286. [95] C. B. Underhill, J. Cell Sci. 1982, 56, 177. [96] E. Vachon, R. Martin, V. Kwok, V. Cherepanov, C. W. Chow,\nC. M. Doerschuk, J. Plumb, S. Grinstein, G. P. Downey, Blood 2007, 110, 4492. [97] G. Y. Lee, J. H. Kim, K. Y. Choi, H. Y. Yoon, K. Kim, I. C. Kwon, K. Choi, B. H. Lee, J. H. Park, I. S. Kim, Biomaterials 2015, 53, 341. [98] S. Banerji, J. Ni, S.-X. Wang, S. Clasper, J. Su, R. Tammi, M. Jones, D. G. Jackson, J. Cell Biol. 1999, 144, 789.\n[99] C. M. Milner, A. J. Day, J. Cell Sci. 2003, 116, 1863. [100] J. R. E. Fraser, T. C. Laurent, U. B. G. Laurent, J. Intern. Med. 1997,\n242, 27. [101] T. I. Morales, V. C. Hascall, J. Biol. Chem. 1988, 263, 3632. [102] R. Tammi, A.-M. Säämänen, H. I. Maibach, M. Tammi, J. Invest.\nDermatol.126, 1991, 97. [103] E. Chain, E. Duthie, Br. J. Exp. Pathol. 1940, 21, 324. [104] A. B. Csóka, S. W. Scherer, R. Stern, Genomics 1999, 60, 356. [105] A. B. Csoka, G. I. Frost, R. Stern, Matrix Biol. 2001, 20, 499.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (17 of 18)\nAdv. Mater. 2019, 1803549\n[106] Z. Liang, Q. Zhang, C. Wang, F. Shi, H. Cao, Y. Yu, M. Zhang, X. Liu, Neoplasma 2017, 64, 901. [107] A. R. Poole, J. Witter, N. Roberts, F. Piccolo, R. Brandt, J. Paquin, M. Baron, Arthritis Rheum. 1990, 33, 790. [108] C. O. McAtee, J. J. Barycki, M. A. Simpson, Adv. Cancer Res. 2014, 123, 1. [109] T. Chanmee, P. Ontong, N. Itano, Cancer Lett. 2016, 375, 20. [110] H. Bouga, I. Tsouros, D. Bounias, D. Kyriakopoulou,\nM. S. Stavropoulos, N. Papageorgakopoulou, D. A. Theocharis, D. H. Vynios, BMC Cancer 2010, 10, 499. [111] S. H. Hautmann, V. B. Lokeshwar, G. L. Schroeder, F. Civantos, R. C. Duncan, R. Gnann, M. G. Friedrich, M. S. Soloway, J. Urol. 2001, 165, 2068. [112] E. J. Franzmann, G. L. Schroeder, W. J. Goodwin, D. T. Weed, P. Fisher, V. B. Lokeshwar, Int. J. Cancer 2003, 106, 438. [113] N. Junker, S. Latini, L. N. Petersen, P. E. Kristjansen, Oncol. Rep. 2003, 10, 609. [114] B. Delpech, A. Laquerriere, C. Maingonnat, P. Bertrand, P. Freger, Anticancer Res. 2002, 22, 2423. [115] K. L. Chao, L. Muthukumar, O. Herzberg, Biochemistry 2007, 46, 6911. [116] S. Hautmann, M. Toma, M. F. L. Gomez, M. G. Friedrich,\nT. Jaekel, U. Michl, G. L. Schroeder, H. Huland, K.-P. Juenemann, V. B. Lokeshwar, Eur. Urol. 2004, 46, 466. [117] L. Udabage, G. R. Brownlee, S. K. Nilsson, T. J. Brown, Exp. Cell Res. 2005, 310, 205. [118] J. X. Tan, X. Y. Wang, X. L. Su, H. Y. Li, Y. Shi, L. Wang, G. S. Ren, PLoS One 2011, 6, e22836. [119] A. G. Bharadwaj, N. P. Goodrich, C. O. McAtee, K. Haferbier, G. G. Oakley, J. K. Wahl III, M. A. Simpson, Exp. Cell Res. 2011, 317, 1214. [120] R. Kohen, A. Nyska, Toxicol. Pathol. 2002, 30, 620. [121] J. Liang, D. Jiang, P. W. Noble, Adv. Drug Delivery Rev. 2016, 97, 186. [122] J. E. Shively, H. E. Conrad, Biochemistry 1976, 15, 3932. [123] B. M. Singh, D. M. Jackson, R. Wills, J. Davies, P. H. Wise, BMJ\n1992, 304, 1154. [124] T. M. Tamer, Interdiscip. Toxicol. 2013, 6, 111. [125] K. Y. Choi, O. F. Silvestre, X. Huang, N. Hida, G. Liu, D. N. Ho,\nS. Lee, S. W. Lee, J. I. Hong, X. Chen, Nat. Protoc. 2014, 9, 1900. [126] H. Kim, H. T. Park, Y. M. Tae, W. H. Kong, D. K. Sung, B. W. Hwang, K. S. Kim, Y. K. Kim, S. K. Hahn, Biomaterials 2013, 34, 8478. [127] K.-S. Tücking, V. Grützner, R. E. Unger, H. Schönherr, Macromol. Rapid Commun. 2015, 36, 1248. [128] J. G. Rho, H. S. Han, J. H. Han, H. Lee, V. Q. Nguyen, W. H. Lee,\nS. Kwon, S. Heo, J. Yoon, H. H. Shin, E.-y. Lee, H. Kang, S. Yang, E. K. Lee, J. H. Park, W. Kim, J. Controlled Release 2018, 279, 89. [129] T. J. Beldman, M. L. Senders, A. Alaarg, C. Pérez-Medina, J. Tang, Y. Zhao, F. Fay, J. Deichmöller, B. Born, E. Desclos, N. N. van der Wel, R. A. Hoebe, F. Kohen, E. Kartvelishvily, M. Neeman, T. Reiner, C. Calcagno, Z. A. Fayad, M. P. J. de Winther, E. Lutgens, W. J. M. Mulder, E. Kluza, ACS Nano 2017, 11, 5785. [130] R. Heo, J.-S. Park, H. J. Jang, S.-H. Kim, J. M. Shin, Y. D. Suh, J. H. Jeong, D.-G. Jo, J. H. Park, J. Controlled Release 2014, 192, 295. [131] K. Y. Choi, E. J. Jeon, H. Y. Yoon, B. S. Lee, J. H. Na, K. H. Min, S. Y. Kim, S. J. Myung, S. Lee, X. Chen, I. C. Kwon, K. Choi, S. Y. Jeong, K. Kim, J. H. Park, Biomaterials 2012, 33, 6186. [132] J. M. Shin, S.-H. Kim, T. Thambi, D. G. You, J. Jeon, J. O. Lee, B. Y. Chung, D.-G. Jo, J. H. Park, Chem. Commun. 2014, 50, 7632. [133] R. Heo, H. Y. Yoon, H. Ko, J. M. Shin, J. Jeon, Y. S. Chae, Y. M. Kang, D. Kim, D. S. Lee, J. H. Park, Chem. Commun. 2015, 51, 16656. [134] E. C. Dreaden, S. W. Morton, K. E. Shopsowitz, J.-H. Choi, Z. J. Deng, N.-J. Cho, P. T. Hammond, ACS Nano 2014, 8, 8374. [135] S. H. Bhang, N. Won, T.-J. Lee, H. Jin, J. Nam, J. Park, H. Chung, H.-S. Park, Y.-E. Sung, S. K. Hahn, B.-S. Kim, S. Kim, ACS Nano 2009, 3, 1389.\n[136] D. Park, Y. Cho, S.-H. Goh, Y. Choi, Chem. Commun. 2014, 50, 15014. [137] H. Chen, B. Qi, T. Moore, F. Wang, D. C. Colvin, L. D. Sanjeewa, J. C. Gore, S.-J. Hwu, O. T. Mefford, F. Alexis, J. N. Anker, Small 2014, 10, 3364. [138] H. Kim, W. H. Kong, K.-Y. Seong, D. K. Sung, H. Jeong, J. K. Kim, S. Y. Yang, S. K. Hahn, Biomacromolecules 2016, 17, 3694. [139] Z. He, P. Zhang, Y. Xiao, J. Li, F. Yang, Y. Liu, J.-R. Zhang, J.-J. Zhu, Nano Res. 2018, 11, 929. [140] X. Wang, H. Chen, K. Zhang, M. Ma, F. Li, D. Zeng, S. Zheng, Y. Chen, L. Jiang, H. Xu, J. Shi, Small 2014, 10, 1403. [141] H. Hyun, K. Lee, K. H. Min, P. Jeon, K. Kim, S. Y. Jeong, I. C. Kwon, T. G. Park, M. Lee, J. Controlled Release 2013, 170, 352. [142] Z. Chen, Z. Liu, Z. Li, E. Ju, N. Gao, L. Zhou, J. Ren, X. Qu, Biomaterials 2015, 39, 15. [143] X. Zhang, M. Yao, M. Chen, L. Li, C. Dong, Y. Hou, H. Zhao, B. Jia, F. Wang, ACS Appl. Mater. Interfaces 2016, 8, 25650. [144] J. H. Park, S. Lee, J.-H. Kim, K. Park, K. Kim, I. C. Kwon, Prog. Polym. Sci. 2008, 33, 113. [145] J.-W. Yoo, D. J. Irvine, D. E. Discher, S. Mitragotri, Nat. Rev. Drug Discovery 2011, 10, 521. [146] D. Cheng, W. Han, K. Yang, Y. Song, M. Jiang, E. Song, Talanta 2014, 130, 408. [147] R. Chib, S. Raut, R. Fudala, A. Chang, M. Mummert, R. Rich, Z. Gryczynski, I. Gryczynski, Curr. Pharm. Biotechnol. 2013, 14, 470. [148] R. Fudala, M. E. Mummert, Z. Gryczynski, I. Gryczynski, J. Photochem. Photobiol., B 2011, 104, 473. [149] J. Kim, Y. Chong, H. Mok, Macromol. Biosci. 2014, 14, 881. [150] Y. Cho, H. Kim, Y. Choi, Chem. Commun. 2013, 49, 1202. [151] M. Swierczewska, K. Y. Choi, E. L. Mertz, X. Huang, F. Zhang,\nL. Zhu, H. Y. Yoon, J. H. Park, A. Bhirde, S. Lee, X. Chen, Nano Lett. 2012, 12, 3613. [152] L. Zhang, S. Gao, F. Zhang, K. Yang, Q. Ma, L. Zhu, ACS Nano 2014, 8, 12250. [153] X. Wang, J.-T. Chen, H. Zhu, X. Chen, X.-P. Yan, Anal. Chem. 2013, 85, 10225. [154] H. Lee, K. Lee, I. K. Kim, T. G. Park, Adv. Funct. Mater. 2009, 19, 1884. [155] H. Y. Yoon, H. Koo, K. Y. Choi, S. J. Lee, K. Kim, I. C. Kwon, J. F. Leary, K. Park, S. H. Yuk, J. H. Park, K. Choi, Biomaterials 2012, 33, 3980. [156] A.-A. Nahain, J.-E. Lee, J. H. Jeong, S. Y. Park, Biomacromolecules 2013, 14, 4082. [157] G. Sahay, W. Querbes, C. Alabi, A. Eltoukhy, S. Sarkar, C. Zurenko, E. Karagiannis, K. Love, D. Chen, R. Zoncu, Y. Buganim, A. Schroeder, R. Langer, D. G. Anderson, Nat. Biotechnol. 2013, 31, 653. [158] L. Rajendran, H.-J. Knölker, K. Simons, Nat. Rev. Drug Discovery 2010, 9, 29. [159] S.-Y. Han, H. S. Han, S. C. Lee, Y. M. Kang, I.-S. Kim, J. H. Park, J. Mater. Chem. 2011, 21, 7996. [160] Z. Wang, Z. Chen, Z. Liu, P. Shi, K. Dong, E. Ju, J. Ren, X. Qu, Biomaterials 2014, 35, 9678. [161] K. Li, H. Liu, W. Gao, M. Chen, Y. Zeng, J. Liu, L. Xu, D. Wu, Biomaterials 2015, 39, 131. [162] J. Jeon, N. V. Rao, J. H. Byun, R. Heo, H. S. Han, J. H. Park, J. Nanosci. Nanotechnol. 2016, 16, 11849. [163] M. M. Alam, H. S. Han, S. Sung, J. H. Kang, K. H. Sa, H. Al Faruque, J. Hong, E. J. Nam, I. S. Kim, J. H. Park, Y. M. Kang, J. Controlled Release 2017, 252, 62. [164] H. Y. Yoon, H. Koo, K. Y. Choi, I. Chan Kwon, K. Choi, J. H. Park, K. Kim, Biomaterials 2013, 34, 5273. [165] L. Qiu, M. Qiao, Q. Chen, C. Tian, M. Long, M. Wang, Z. Li, W. Hu, G. Li, L. Cheng, L. Cheng, H. Hu, X. Zhao, D. Chen, Biomaterials 2014, 35, 9877.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1803549 (18 of 18)\nAdv. Mater. 2019, 1803549\n[166] J. Qiu, R. Cheng, J. Zhang, H. Sun, C. Deng, F. Meng, Z. Zhong, Biomacromolecules 2017, 18, 3207. [167] J. Han, W. Park, S.-j. Park, K. Na, ACS Appl. Mater. Interfaces 2016, 8, 7739. [168] H. Y. Yoon, H. R. Kim, G. Saravanakumar, R. Heo, S. Y. Chae, W. Um, K. Kim, I. C. Kwon, J. Y. Lee, D. S. Lee, J. C. Park, J. H. Park, J. Controlled Release 2013, 172, 653. [169] K.-m. Choi, M. Jang, J. H. Kim, H. J. Ahn, Biomaterials 2014, 35, 7121. [170] J. Ding, T. Liang, Y. Zhou, Z. He, Q. Min, L. Jiang, J. Zhu, Nano Res. 2017, 10, 690. [171] H. Yim, W. Park, D. Kim, T. M. Fahmy, K. Na, Biomaterials 2014, 35, 9912. [172] M. Zhang, C. Xu, L. Wen, M. K. Han, B. Xiao, J. Zhou, Y. Zhang, Z. Zhang, E. Viennois, D. Merlin, Cancer Res. 2016, 76, 7208. [173] T. Yin, L. Wang, L. Yin, J. Zhou, M. Huo, Biomaterials 2015, 61, 10. [174] R. Mo, T. Jiang, R. DiSanto, W. Tai, Z. Gu, Nat. Commun. 2014, 5. [175] X. Liang, L. Fang, X. Li, X. Zhang, F. Wang, Biomaterials 2017, 132, 72. [176] H. S. Han, J. Lee, H. R. Kim, S. Y. Chae, M. Kim, G. Saravanakumar, H. Y. Yoon, D. G. You, H. Ko, K. Kim, I. C. Kwon, J. C. Park, J. H. Park, J. Controlled Release 2013, 168, 105."
    } ],
    "references" : [ {
      "title" : "Adv",
      "author" : [ "Z. Yang", "Y. Dai", "C. Yin", "Q. Fan", "W. Zhang", "J. Song", "G. Yu", "W. Tang", "W. Fan", "B.C. Yung", "J. Li", "X. Li", "X. Li", "Y. Tang", "W. Huang", "J. Song", "X. Chen" ],
      "venue" : "Mater.30",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "J",
      "author" : [ "R. Tammi", "A.-M. Säämänen", "H.I. Maibach", "M. Tammi" ],
      "venue" : "Invest. Dermatol.126",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 1991
    }, {
      "title" : "2001",
      "author" : [ "S.H. Hautmann", "V.B. Lokeshwar", "G.L. Schroeder", "F. Civantos", "R.C. Duncan", "R. Gnann", "M.G. Friedrich", "M.S. Soloway", "J. Urol" ],
      "venue" : "165",
      "citeRegEx" : "111",
      "shortCiteRegEx" : null,
      "year" : 2068
    }, {
      "title" : "Nat",
      "author" : [ "K.Y. Choi", "O.F. Silvestre", "X. Huang", "N. Hida", "G. Liu", "D.N. Ho", "S. Lee", "S.W. Lee", "J.I. Hong", "X. Chen" ],
      "venue" : "Protoc. 2014, 9",
      "citeRegEx" : "125",
      "shortCiteRegEx" : null,
      "year" : 1900
    } ],
    "referenceMentions" : [ {
      "referenceID" : 1,
      "context" : "[100] For example, HA in the vitreous of the eye has a long half-life of 70 days, whereas HA in the skin has a short half-life of ≈1 day.[101,102] Regardless of the anatomical location, a specific family of enzymes, hyaluronidases, controls the degradation of HA, which directly cleave the β-N-acetyl-d-glucosaminidic bond in the HA chain[103] due to specific structural features of Hyals.",
      "startOffset" : 137,
      "endOffset" : 146
    }, {
      "referenceID" : 3,
      "context" : "Zn-DPA-labeled HA–CA NPs siRNA delivery [39,125]",
      "startOffset" : 40,
      "endOffset" : 48
    }, {
      "referenceID" : 3,
      "context" : "By taking advantage of the rapid degradation by Hyals, this strategy enabled a rapid burst-release of imaging and/or therapeutic agents at the local diseased tissue.[38,39,125,155] In addition to optical imaging, photoacoustic imaging is addressable using HA nanoparticles.",
      "startOffset" : 165,
      "endOffset" : 180
    } ],
    "year" : 2019,
    "abstractText" : "Dr. K. Y. Choi, Dr. H. S. Han, J. M. Shin, Prof. D. S. Lee, Prof. J. H. Park School of Chemical Engineering College of Engineering Sungkyunkwan University Suwon 16419, Republic of Korea E-mail: jhpark1@skku.edu Dr. K. Y. Choi, Dr. H. S. Han Natural Product Informatics Research Center Korea Institute of Science and Technology Gangneung 25451, Republic of Korea E. S. Lee, Prof. J. H. Park Department of Health Sciences and Technology SAIHST Sungkyunkwan University Suwon 16419, Republic of Korea Dr. B. D. Almquist Department of Bioengineering Imperial College London SW7 2AZ London, UK Prof. D. S. Lee Theranostic Macromolecules Research Center Sungkyunkwan University Suwon 16419, Republic of Korea The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201803549.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}